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ABSTRACT

Nigella sativa derivatives, thymoquinone (TM) and dithy
moquinone (DIM) are used in treatment of parental and
multi-drug resistant human cancers.
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USE OF THE NATURALLY-OCCURRING

genesis in mice. Intraperitoneal injections of the same black

QUINONES THYMOQUINONE AND

seed extract may reduce the incidence of soft tissue sarco
mas observed after 30 days of subcutaneous

DITHYMOQUINONE AS ANTINEOPLASTIC

20-methylcholanthrene (MCA) injections by 67% as com
pared to MCA-treated controls. Another chemoprotective

AND CYTOTOXIC AGENTS
CLAIM OF PRIORITY

effect is treatment With a crude ethanolic extract of

This application claims priority to Provisional Applica
tion Ser. No. 60/087,074, ?led May 28, 1998.
FIELD OF THE INVENTION

10

not establish the anti-cancer activity of speci?c blackseed

The present invention relates to the use of Nigella sativa
derivatives in the treatment of carcinoma. More speci?cally,
the invention relates to the use of the derivatives thymo

quinone (TO) and dithymoquinone (DIM) in the treatment

components, in particular that of the quinones thymo
quinone (TO) and dithymoquinone (DIM). Further, no stud
15

of parental and multi-drug resistant (MDR) human cancers.
BACKGROUND OF THE INVENTION

Various anti-cancer drugs (a.k.a., antineoplastic agents)
are Widely used for treatment of both tumorous and leuke
mic parental cancer cells. Certain cell lines, hoWever, are

ation and rational therapeutic development of these agents.
20

SUMMARY OF THE INVENTION

It is accordingly an aspect of the invention to provide

drugs are MDR substrates. MDR, a phenomenon character

methods and compositions for effectively treating both
25

anticancer drugs, including quinones, seriously complicates

a natural source.

It is yet another aspect of the invention to provide
methods and compositions, as above, Which employ an

MDR cell lines are over 10-fold more resistant to the Well

knoWn antineoplastic agents doxorubicin (DOX) and eto
poside (ETP). Accordingly, there is a constant search for

extract from a natural source Which is inexpensive and

readily available.
These objects and others set forth beloW are achieved by
35

such agents. Blackseed, the seed of Nigella sativa L.
[Ranunculaceae], has been employed for thousands of years

a compound selected from the group consisting of

40

blackseed referred to by the prophet Mohammed as having

gum, ?xed oil and tWo puri?ed components of Nigella sativa
seed, TO and DIM, Were assayed in vitro for their cytotox

icity for several parental and multi-drug resistant (MDR)

healing poWers; blackseed is also identi?ed as the curative
black cumin in the Holy Bible, and is described as the
Melanthion of Hippocrates and Doscorides and as the Gith

of Pliny. Several bene?cial pharmacological effects have

treating cancer in an individual in need of such treatment by
administering to said individual an antineoplastic amount of

thymoquinone, dithimoquinone, and mixtures thereof.
To establish antineoplastic and cytotoxic activity, a crude

as a spice and food preservative, as Well as a protective and

curative remedy for numerous disorders. The historical
tradition of blackseed in medicine is substantial. It is the

parental and multi-drug resistant cancers.
It is another aspect of the invention to provide methods
and compositions, as above, Which employ an extract from

and compromises the effective chemotherapy of cancer. For
example, as compared to their parental counterparts, many

antineoplastic agents that are not MDR substrates and Which
are therefore capable of effectively treating MDR cancers.
Naturally occurring substances are a promising source for

ies have been reported Which evaluate the cytotoxicity of the
Nigella sativa seed components TO and DIM for multi-drug
resistant cancer cells. Thus, comprehensive cytotoxicity
assays of these potential anticancer drugs in both parental
and MDR tumor cell lines are useful for a thorough evalu

multi-drug resistant (MDR) and many standard anti-cancer

iZed by over-expression of the mdr1 gene product
P-glycoprotein and cross-resistance to multiple classes of

blackseed, Which may signi?cantly reduce cisplatin-induced
leukopenia and hemoglobinemia in cisplatin-treated mice.
Although the above applications illustrate the antine
oplastic potential of crude blackseed preparations, they do

45

human tumor cell lines. Although as much as 1% W/v of the
gum or oil Was devoid of cytotoxicity, both TO and DIM
Were cytotoxic for all of the tested cell lines ICSO’s 78 to 393

been attributed to various crude and puri?ed components of

pM. Both the parental cell lines and their corresponding

blackseed, including antihistaminergic, antihypertensive,

MDR variants, over 10-fold more resistant to the standard

hypoglycemic, antimicrobial, mast cell stabiliZing and anti
in?ammatory activities.
Blackseed preparations may have signi?cant in vitro and
in vivo antineoplastic activity. A crude methanolic extract of

antineoplastic agents doxorubicin (DOX) and etoposide
(ETP), as compared to their respective parental controls,
50

Nigella sativa seed has an in vitro IC5O to Erlich ascites
carcinoma, Dalton’s ascites lymphoma and sarcoma 180

cells of 1.5, 3 and 1.5 pg/mL, respectively, While exerting
minimal cytotoxicity to normal lymphocytes. This extract is

55

also active in vivo, completely inhibiting the groWth of
Erlich ascites carcinoma in mice. Exposure to the volatile oil
obtained from blackseed is believed to alter the cellular

expression of speci?c polypeptides in Jurkart T lymphoma
cells, suggesting that changes in polypeptide expression

60

might play a role in the biological activities attributed to
blackseed. In addition to these direct anti-tumor effects,
blackseed preparations may have potential for cancer
chemoprevention, as Well as for reducing the toxicity of

standard antineoplastic drugs. Topical application of a black
seed extract can inhibit the tWo-stage initiation-promotion

(by dimethylbenZ[a]anthracene-croton oil) of skin carcino

Were equally sensitive to TO and DIM. The inclusion of the

competitive MDR modulator quinine in the assay reversed
MDR Dx-5 cell resistance to DOX and ETP by 6- to 16-fold,
but had no effect on the cytotoxicity of TQ or DIM. Quinine
also reduced MDR Dx-5 cell accumulation of the
P-glycoprotein substrate 3H-taxol in a dose-dependent man
ner. HoWever, neither TQ nor DIM signi?cantly altered
cellular accumulation of 3H-taxol. The inclusion of 0.5% v/v
of the radical scavenger DMSO in the assay reduced the
cytotoxicity of DOX by as much as 39%, but did not affect
that of TQ or DIM. This suggests that TO and DIM, Which
are cytotoxic for several types of human tumor cells, may
not be MDR substrates, and that radical generation may not

be critical to their cytotoxic activity.
BRIEF DESCRIPTION OF THE DRAWINGS
65

For a full understanding of the invention, the folloWing
detailed description should be read in conjunction With the
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drawing, Which is a bar graph of the effect of serial con
centrations of QUIN, TQ and DIM in H-taxol accumulation
assays.

DMSO reduces the in vitro cytotoxicity of radical

DETAILED DESCRIPTION

mechanisms responsible for their in vitro anti-cancer activ

generating quinones such as DOX (21). Thus, the effect, if
any, of DMSO on the toxicity of the blackseed components

assayed herein is thought to provide insight into the speci?c

ity.

It has been discovered that the quinones TQ and DIM, tWo

The folloWing example illustrates the invention.

important constituents of Nigella sativa seed, are cytotoxic
for several types of human tumor cells in vitro. In contrast,
neither the ?xed oil nor the crude gum preparation obtained

from Nigella sativa seed exert signi?cant cytotoxic activity
for any of the assayed tumor cell lines. Notably, both TQ and
DIM are equally cytotoxic for both parental and MDR tumor
cells. Their cytotoxicity Was not modulated by the presence
of 6 pg/mL quinine, a competitive P-gp substrate that
reverses MDR cell resistance to DOX and ETP by as much

as 16-fold. Further, although serial concentrations of QUIN
increase MDR Dx-5 cell uptake of the MDR substrate taxol
in a dose-dependent manner, neither TQ nor DIM signi?
cantly alter MDR Dx-5 cellular accumulation of taxol. These
data suggest that these cytotoxic compounds are not
P-glycoprotein substrates. Thus, they can function as useful
anticancer drugs, as Well as lead compounds for novel agents

EXAMPLE
10

Blackseed (Nigella sativa seed) and the expressed oil of
blackseed Were purchased from Al-BadaWin (Cairo, Egypt).

Thymoquinone (TQ), ethylenediaminetetraacetic acid
(EDTA) and methylthiaZoltetraZolium bromide (MTT) Were
15

The radical scavenger DMSO, employed both experimen
tally and clinically to reduce the toxicity of radical gener
ating quinones such as DOX, signi?cantly reduced the
effective in vitro toxicity of DOX for 4 of the 5 cell lines
tested. HoWever, the inclusion of DMSO in the cytotoxicity
assays did not modulate the toxicity of TQ or DIM, sug

obtained from Sigma (St. Louis, Mo.). HPLC-grade metha
nol and dimethyl sulfoxide (DMSO) Were purchased from

Fisher Scienti?c (Spring?eld, N.J.). Doxorubicin
(Adriamycin, DOX) Was purchased from Adria Laboratories

(Columbus, Ohio); Etoposide (Vepesid, ETP) Was obtained
20

from Bristol Myers Squibb (Princeton, N.J
Preparation of blackseed gum and dithymoquinone.
5 g of blackseed Were pulveriZed in a Wiley mill (20
gauge mesh) and stirred in the dark at room temperature for

designed to treat MDR tumors resistant to standard antine

oplastics.

Materials.

72 hours in 500 mL methanol. The extract Was vacuum
25

?ltered across Whatman No. 1 ?lter paper (Maidstone,

England, UK) and the ?ltrate concentrated in a rotary
evaporator in vacuo at 40° C., leaving 1.1 mL of a clear oil
and 0.45 g of a greenish-White gum. The oil Was separated

from the gum by exhaustive aspiration through a pipette, and
30

gesting that these compounds may exert their cytotoxic
effects through mechanisms other than radical generation.
This characteristic might be particularly bene?cial if these

the gum Was assayed for its cytotoxic activity as described
beloW.

Dithymoquinone (DIM) Was prepared by the
UV-catalyZed dimeriZation of TQ and puri?ed by multiple
recrystalliZations from ethanol, yielding a pale yelloW poW

compounds Were employed to treat those tumors resistant to 35 der. The identity and purity of DIM Were veri?ed using

standard agents by virtue of their expression of high levels

1H-NMR, 13C-NMR, melting point determination and

of cellular antioxidants and antioxidant enZymes.

HPLC analysis using Well knoWn techniques.

Crude gum and expressed oil preparations from
blackseed, as Well as the puri?ed quinones TQ and DIM
have been evaluated in vitro for their cytotoxicity for the
human pancreatic adenocarcinoma cell line CFPAC-1, the

40

human uterine sarcoma cell line MES-SA and its MDR

variant, Dx-5, and for the human leukemic cell line K562
and its MDR variant, R7. Both Dx-5 and R7 cells are
generally some 25- to 60-fold resistant to various MDR 45

Cell culture.
The human pancreatic adenocarcinoma cell line CFPAC
1, the human uterine sarcoma cell lines MES-SA (parental)
and Dx5 (MDR) and human leukemic cell lines K562

(parental) and R7 (MDR) Were purchased from AT CC
(Rockville, Md.). All cell lines Were maintained in McCoy’s
5A medium supplemented With 10% neWborn calf serum,

100 U/mL penicillin and 100 (ug/mL streptomycin (GIBCO

substrates including paclitaxel, Vinca alkaloids and to

BRL, Grand Island,

quinones such as doxorubicin (DOX). These cell lines Were
chosen in order to evaluate the cytotoxicity of blackseed
components for both solid and leukemic tumor cell lines, as
Well as to evaluate the relative sensitivity of MDR tumor
cells to the cytotoxic effects of TQ and DIM. In order to

tissue culture ?asks (DoW Corning, Corning, NY.) at 37° C.
in a humidi?ed atmosphere (5% CO2/95% air) and subcul
50

The cells Were cultured in 75 cm3

tured at con?uence every 3—4 days after detaching adherent
cells With 0.4% EDTA in PBS.

further determine Whether or not TQ and DIM are MDR

MTT cell viability assay.
Cells Were plated in 96-well microtiter plates (DoW

substrates, analogous cytotoxicity experiments Were con
ducted in the presence of quinine (QUIN), a quinoline

Corning, Corning, NY.) at a density of 1><104 cells/Well in

alkaloid and competitive MDR substrate proven to reverse
the MDR defect and signi?cantly increase tumor cell sen

55

sitivity to MDR substrates, both in vitro and in vivo. Thus,
the effect of QUIN on MDR tumor cell sensitivity to TQ and
DIM might further clarify Whether or not these blackseed
quinones are MDR substrates. An evaluation of the effect of
QUIN, TQ and DIM on MDR Dx-5 cellular accumulation of
the P-gp substrate 3H-taxol Was conducted in order to further

tions of the gum, DOX or ETP dissolved in PBS and ?ltered

through a 0.2 pM ?lter, and 0.2 M sterile-?ltered stock
solutions of the ?xed oil, TQ or DIM dissolved in methanol
Were diluted With normal media to prepare the serial con

clarify Whether or not TQ and DIM are MDR substrates.

In addition to assaying the cytotoxicity of TQ and DIM
for MDR tumor cells, the cytotoxicity of TQ and DIM in the
presence of the radical scavenger dimethylsulfoxide
(DMSO) Was also examined. Concurrent treatment With

100 pL media and incubated for 24 hours. The spent media
Was then carefully and uniformly aspirated from each Well
With a microtiter pipette and replaced With either 100 pL
fresh control media or 100 ML media containing the speci?ed
concentration of the tested compounds. Sterile stock solu

centrations of the various compounds. Control cytotoxicity
assays revealed that the highest concentration of methanol
65

used in the studies, 2% v/v, Was not toxic for any cell line.
After exposure to serial concentrations of the speci?ed

compounds for 72 hours, the spent control and drug

US 6,218,434 B1
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containing media Were aspirated and 100 ML of fresh media

effects of TQ and DIM. Notable, MDR Dx-5 cells, though

and 100 ML of a solution of 5 mg/mL MTT in PBS Were
added to each Well. The cells Were alloWed to incubate for

their MDR-negative parental cell line MES-SA, Were almost

4 hours, the media aspirated, and the blue intracellular
formaZan product dissolved in 200 ML DMSO. The UV
absorbance of each Well Was immediately determined using
a Dynatech MR 580 Microelisa (test Wavelength 570

10- to 16-fold resistant to DOX and ETP as compared to
tWice as sensitive to DIM as Were the MES-SA cells. The
5

estimated ICSO’s of the assayed compounds in each cell line
are summariZed in the following table.

nm/reference Wavelength 634 nm). Each cytotoxicity assay
TABLE
Cell Line

Drug

CFPAC-l

KSAZ

R7

MES-SA

DX-5

Dox

8.48 1 0.26

0.64 1 0.01

9.94 1 0.4

0.89 1 0.05

8.05 1 0.41

Dox + DMso 8.24 1 0.18
Dox + QUIN

0.76 1 0.05b
0.68 1 0.02

12.1 1 0.5b
0.64 1 003°

1.48 1 0.06b
0.72 1 0.02

ETP
ETP + QUIN
TO
TO + DMso
TO + QUIN
DIM
DIM + DMso
DIM + QUIN

0.39
0.39
275
250
300
277
247
194

15.3
2.95
235
232
265
225
160
161

0.33
0.36
188
156
191
143
143
147

12.5
0.58
4.47
0.56
255
232
243
87
78
80

206 1 8.5
234 1 12.2
386 1 18.5
393 1 15.3

1
1
1
1
1
1
1
1

0.01
0.02
15.1
13.3
13.2
8.9
13.6
12.0

1
1
1
1
1
1
1
1

0.40
0.100
10.9
9.9
10.4
8.5
7.5
5.8

1
1
1
1
1
1
1
1

0.01
0.01
9.8
8.9
8.8
8.7
6.9
5.2

1
1
1
1
1
1
1
1
1
1

0.45b
002°
0.26
0.026
9.4
13.8
16.2
2.8
4.1
3.3

25

As measured by effective ICSO, the inclusion of 6 pg/mL
of the competitive P-gp substrate QUIN in analogous cyto

Was conducted in quadruplicate using tWo independent
experiments. The data Were plotted as linear dose-response
curves of percent cell viability (UV absorbance) as com
pared to untreated controls. IC5O values are presented as the
mean 1 SEM as determined by direct extrapolation from the

toxicity assays reversed MDR R7 tumor cell resistance to

DOX by 15-fold and R7 resistance to ETP by 6-fold (Table
30

curves.

3H-taxol accumulation studies.

I). A similar effect Was observed in MDR Dx-5 cells. In the
presence of 6 pg/mL free QUIN, Dx-5 resistance to DOX
Was reduced by 16-fold, and resistance to ETP by 7-fold. In

contrast, free QUIN in the assay media did not signi?cantly

Tritiated taxol accumulation studies Were carried out

using MDR- MES-SA and MDR+Dx-5 cells. Brie?y, 1><106

alter Dx-5 or R7 cell sensitivity to TQ or DIM. These data
cells Were groWn in 2 mL media in Falcon 35x10 mm sterile 35 indicate that TQ and DIM are equally cytotoxic for both

tissue culture plates (Becton Dickinson, Lincoln Park, N.]

parental and MDR tumor cells, and suggest that these tWo

After alloWing the cells to attach for 24 hours, the spent
media Was aspirated, and 10 ML of 3H-taxol (Amersham
Corp., Arlington Heights, Ill.) Was added to each Well
containing either 1 mL of control media or media containing
the speci?ed concentration of the indicated compound. After
30 minutes incubation, the assay media Was aspirated, the
cells Washed tWice With 1 mL of ice-cold PBS, and the cells
lysed for 1 hour With 1 mL of 4% W/v SDS in deioniZed
Water. The cell digest Was neutraliZed With glacial acetic
acid, and 10 ML aliquots of the lysate Were added to
scintillation vials containing 10 mL of Ecolite scintillation

quinones may not be P-gp substrates. Control cytotoxicity
assays revealed that 6 pg/mL QUIN Was not toxic to any cell
line tested.
40

The effect of including serial concentrations of QUIN, TQ
or DIM in the 3H-taxol accumulation assays is illustrated in

the Figure. MDR Dx-5 cells accumulated only about 20% as
much taxol as compared to non-MDR MES-SA parental
45

cells. The presence of the competitive P-gp blocker QUIN in
the uptake media reduced taxol accumulation signi?cantly
and in a dose-dependent manner. HoWever, neither TQ nor
DIM reversed the accumulation defect in Dx-5 cells. Con
centrations of these quinones as high as 200 MM did no

cocktail (1CN Biomedicals, Irvine, Calif.). Radioactivity
sus accumulation in non-MDR MES-SA cells Was standard

signi?cantly alter cellular accumulation of taxol.
The inclusion of 0.2% v/v of the radical scavenger DMSO
in culture media reduces the cytotoxicity of the quinone

iZed per unit cellular protein present using the bichinconic

DOX to human ovarian tumor cells by as much as 39%.

Was quanti?ed using a Tri Carb C scintillation counter

(Packard, DoWner’s Grove, Ill.). Percent accumulation ver

50

Radiolabelled uptake experiments reveal that this cytopro

acid method as described in Gosland, MP et al., Cancer

Chemother Parmacol, 37:593—600, 1996, Which is hereby

incorporated by reference.

tective effect is not due to a DMSO-mediated decrease in
55 cellular accumulation of DOX. In order to assess the effect

Results.

The quinones TQ and DIM inhibited the groWth of
CFPAC-1 cells in a dose-dependent manner and similarly

inhibited the groWth of K562, R7, MES-SA and Dx-5 cells.
In contrast, neither the ?xed oil nor the crude gum prepa

60

ration demonstrated signi?cant cytotoxic activity to any of

of DMSO on the cytotoxicity of the quinones TQ and DIM,
the previously described cytotoxicity assays Were repeated
in media containing 0.5% v/v DMSO. Although the addition
of 0.5% v/v DMSO did not signi?cantly alter DOX cyto
toxicity to CFPAC-1 cells, DMSO reduced the cytotoxicity
of DOX to K562, R7, MES-SA and Dx-5 cells by 18%, 33%,

the tested cell lines (estimated IC5O >10% W/v oil or gum,

39%, and 22%, respectively (Table I). Interestingly, the

data not shoWn). The MDR cell lines Dx-5 and R7 Were
more than 10-fold resistant to the cytotoxic effects of DOX

cytotoxicity of TQ and DIM for the various cell lines

and ETP as compared to their respective parental controls,
MES-SA and K562. HoWever, both the parental and MDR
variants of these cell lines Were sensitive to the cytotoxic

examined Was not signi?cantly altered When DMSO Was
65

included in the assay media. Although the cytotoxic effects
of quinones such as TQ and DIM could be attributed to a

number of mechanisms, including adduct formation With

US 6,218,434 B1
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nucleophilic residues, the failure of DMSO to modulate their

routes of administration including, but not limited to, the

cytotoxicity in these experiments suggests that radical for

intravenous, intramuscular, intrathecal, intraperitoneal,
intralesional, subcutaneous, intradermal, transdermal,
intranasal, topical, oral, buccal, rectal, vaginal, intrapulmo

mation may be less important to the in vitro cytotoxicity of
TQ and DIM than are other mechanisms. Control cytotox
icity assays reveal that 0.5% v/v DMSO Was not cytotoxic
for any of the tested cell lines.

nary and inhalation routes of administration.
The amount of TQ, DIM or mixture thereof that is used in

The pharmaceutical compositions of the present invention

treatment varies With the siZe and species of the mammal,
the type of cancer, and the method of administration.
Generally, the amount of active compound can vary from

can also include various other components as additives or

adjuncts. Exemplary pharmaceutically acceptable compo
stances include antioxidants, free radical scavenging agents,

about 10—500 mg/kg body Weight per day, and preferably
from about 10—30 mg/kg body Weight per day. The admin

peptides, groWth factors antibiotics, bacteriostatic agents,

istration can be as a single dose or one or more doses

nents or adjuncts Which are employed in relevant circum

10

immunosuppressives, buffering agents, anti-in?ammatory

administered over a 24-hour period. Injections are prefer

agents, anti-pyretics, time release binders, anaesthetics, ste

ably in the form of dilute solutions (e.g. 10—50% v/v) and

roids and corticosteroids. Such components can provide
additional therapeutic bene?t, act to affect the therapeutic
action of the pharmaceutical composition, or act toWards
preventing any potential side effects Which may be posed as
a result of administration of the pharmaceutical composi
tion. In certain circumstances, a compound of the present
invention can be employed as part of a pharmaceutical
composition With other compounds intended to prevent or

15

For topical administration used in the treatment of skin
cancer, a dilute solution (10—50% v/v) may be used in a
suitable corner and applied from 1 to 3 times daily to the
affected area for a period of from 30 days to 6 months.
The invention also includes the use of Nigella sativa

treat a particular disorder.
The manner in Which the compounds are administered can

vary. The compounds can be administered by inhalation
(e.g., in the form of an aerosol either nasally or using
delivery articles of the type set forth in US. Pat. No.

25

components, including TQ, DIM and mixtures thereof, as
Well as all derivatives, congeners and analogues thereof, for
the palliation and/or treatment of solid and/or leukemic
tumors When administered orally in a suitable dosage form
including, but not limited to, the neat compound(s), or any

solution, elixir, syrup, tablet, capsule, suspension, emulsion,
microemulsion or adsorption product containing said
compound(s) and intended for their oral delivery, in the
general dosage range of 1 to 80 mg compound(s)/kg body
Weight, When administered in single or divided doses during
a period of therapy of 1 to 60 days daily, every feW days,
Weekly or monthly as deemed appropriate for therapy by a
quali?ed practitioner of the art.

4,922,901 to Brooks et al.); topically (e.g., in lotion form);
orally (e.g., in liquid form W.
Within a solvent such as an aqueous or non-aqueous

liquid, or Within a solid carrier; intravenously (e.g., Within a
dextrose or saline solution); as an infusion or injection (e.g.,
as a suspension or as an emulsion in a pharmaceutically

acceptable liquid or mixture of liquids); or transdermally
(e.g., using a transdermal patch). Although it is possible to

can be effective in the treatment of tumors and leukemias.

One skilled in the art can monitor the progress of treat
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ment and adjust the length or dose of active ingredient

accordingly.

administer the compounds in the form of a bulk active

chemical, it is preferred to present each compound in the

What is claimed is:
1. A method for treating cancer in an individual in need of

form of a pharmaceutical composition or formulation for

efficient and effective administration. Exemplary methods
for administering such compounds Will be apparent to the
skilled artisan. For example, the compounds can be admin

such treatment, comprising administering to said individual

istered in the form of a tablet, a hard gelatin capsule or as a

mixtures thereof and Wherein the cancer is sensitive the

time release capsule. As another example, the compounds
can be delivered transdermally using the types of patch
technologies available from Novartis and AlZa Corporation.
The administration of the pharmaceutical compositions of

compound.

an antineoplastic amount of a compound selected from the

group consisting of thymoquinone, dithymoquinone, and
2. The method as claimed in claim 1, Wherein said cancer
45

is multi-drug resistant.

continuous, constant or controlled rate to a Warm-blooded

3. The method as claimed in claim 2, Wherein the multi
drug resistant cancer comprises a human leukemia.
4. The method as claimed in claim 1, Wherein the cancer

the present invention can be intermittent, or at a gradual,

animal, (e.g., a mammal such as a mouse, rat, cat, rabbit,

is selected from the group consisting of human pancreatic

dog, pig, coW, or monkey); but advantageously is preferably

adenocarcinoma and human uterine sarcoma.

administered to a human being. In addition, the time of day
and the number of times per day that the pharmaceutical
formulation is administered can vary. Administration pref

is sarcoma, carcinoma or leukemia.

erably is such that the active ingredients of the pharmaceu
tical formulation interact With target site Within the body of

the subject.
In general, the invention includes the use of Nigella sativa
components, including TQ, DIM and mixtures thereof, as
Well as all derivatives, congeners and analogues thereof, for
the palliation or treatment of solid and/or leukemic tumors
in animals and/or humans When administered by any or all

5. The method according to claim 1, Wherein said cancer

6. The method according to claim 5, Wherein said
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sarcoma, carcinoma or leukemia is multi-drug resistant.
7. The method according to claims 5, Wherein said car
cinoma is adenocarcinoma.
8. The method according to claim 5, Wherein said sarcoma
or carcinoma is pancreatic adenocarcinoma or uterine sar
coma.

